Tetraphase performs above average in Research & Development when compared to other small and medium-sized enterprises in scope.
Tetraphase has three antibacterial projects in its pipeline that target priority pathogens, including one candidate for the treatment of serious and life-threatening multidrug-resistant bacterial infections caused by pathogens including Carbapenem-resistant Enterobacteriaceae (CRE) and Carbapenem-resistant A. baumannii (CRAB). Reports project-specific access and stewardship plans for its recently approved medicine, eravacycline.
Sales & Operations
Sales & Operations
Therapeutic areas: Antibiotics Products on the market: 1, eravacycline (Xerava™) approved in August 2018 for the treatment of complicated intra-abdominal infections R&D grants received since 2016: At least USD 4 million, awarded by one funder (CARB-X). The award, worth USD 4 million, was granted in March 2017 to support its pipeline candidate TP-6076 which has demonstrated potent activity against multidrug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae and carbapenem-resistant A. baumannii. Financing and investment structure: Tetraphase is a publicly listed company. It completed its IPO in March 2013 raising USD 75 million, following four funding series raising USD 95 million. Its lead investors were Excel Venture Management and Mediphase Venture Partners. M&A since 2018: None in the antibacterial and/or antifungal sectors
Pipeline & Portfolio
for diseases in scope
Pipeline size: 3 projects for priority pathogens* (3 antibacterial medicines) Development stages: 2 clinical projects, including TP-271, a Phase I clinical candidate for the treatment of respiratory disease caused by bacterial biothreats and antibacterial-resistant public health pathogens Novelty: No novel clinical-stage medicine projects Regulatory approvals: 1, for eravacycline (Xerava™) for the treatment of complicated intra-abdominal infections in 2018 Access plans: Its 1 late-stage R&D project has a project-specific access plan which includes a commitment to addressing affordability through licensing agreements. Stewardship plans: Its 1 late-stage R&D medicine project has a project-specific stewardship plan which includes the development of a surveillance network for bacterial susceptibility to eravacycline.
Opportunities for Tetraphase
Expand the implementation of the access and stewardship plans for eravacycline (Xerava™). Tetraphase has already implement access and stewardship plans (including a license to Everest Medicines in the ASEAN region and a surveillance programme) for eravacycline, its antibacterial candidate that recently was approved. Tetraphase can also implement its commitment to addressing affordability through licensing agreements that would supply this medicine in other markets, like Latin American and Africa countries. In order to promote appropriate use of eravacycline, Tetraphase can decouple sales incentives from sales volumes and consider publicly sharing raw data collected for its long-term, multinational surveillance programme.
Changes since 2018
Changes since 2018
Received FDA approval in August 2018 for eravacycline (Xerava™) for the treatment of complicated intra-abdominal infections.
Entered into a global-level development and commercialisation agreement in 2018 with Everest Medicines for eravacycline in China, Taiwan, Hong Kong, Macau, South Korea, Singapore, Thailand, Indonesia, Philippines and Malaysia.
Performance by research area
Research & Development
Indicators scored on
Evaluated: medicine & vaccine pipelines for priority* bacteria & fungi
A.1 R&D investments Tetraphase invested USD 156.6 million in the development of antibacterial medicines in 2017 and 2018. As with all other SMEs evaluated, Tetraphase was not scored in this indicator.
A.2.1 Pipeline size of three projects Tetraphase reports three projects targeting priority pathogens in its pipeline. The company focuses on antibacterial medicine development, and has two projects in clinical development, in addition to its recently approved product eravacycline (Xerava™).
A.2.2 No clinical-stage novel projects Tetraphase’s clinical-stage medicine pipeline for priority pathogens consists entirely of new R&D projects. It does not currently include candidates that are considered novel. However, Tetraphase has three clinical-stage new R&D projects, including TP-6076 for the treatment of serious and life-threatening multidrug-resistant bacterial infections caused by pathogens including CRE and CRAB, among others.
A.2.3 Vaccines in the pipeline Tetraphase is not eligible for this indicator as it is not active in vaccine development.
A.2.4 Two candidates targeting critical priorities Tetraphase’s clinical pipeline includes one antibacterial medicine in Phase I: TP-6076, which targets CRE and CRAB. The company also has a recently approved medicine, eravacycline (Xerava™), which targets CRE, N. gonorrhoeae and resistant strains of A. baumannii. These pathogens are among those that are considered critical and/or urgent R&D priorities for limiting AMR, as identified by WHO and/or the US Centers for Disease Control and Prevention (CDC).
A.3 Intellectual capital sharing As an SME, Tetraphase was not scored for this indicator, in line with the external stakeholder consensus defined by the Foundation.
A.4 Access and stewardship plan for 1 project Tetraphase has one late-stage R&D project targeting a priority pathogen. Tetraphase has a licensing agreement for eravacycline (Xerava™)that enables the licensee to market the product at a competitive price in countries belonging to the Association of Southeast Asian Nations (ASEAN). Tetraphase has also committed to addressing affordability through licensing agreements that would supply this medicine in other markets. Further, Tetraphase is collaborating with International Health Management Associates (IHMA), an independent laboratory with expertise in surveillance and clinical trials, to develop a surveillance network looking at susceptibilities to eravacycline in different pathogens and clinical settings. Tetraphase provides the medicine, as well as testing strips and disks, to help hospitals and researchers test it against isolates.
Pipeline targeting priority pathogens: 3
As a small- to medium-sized enterprise (SME), Tetraphase is not evaluated in this Research Area. It has one antibacterial product on the market: the antibacterial eravacycline (Xerava™).
Access & Stewardship
As a small- to medium-sized enterprise (SME), Tetraphase is not evaluated in this Research Area. It has one antibacterial and/or antifungal product on the market: the antibacterial eravacycline (Xerava™). The Benchmark notes that it is active in one AMR surveillance programme, and that it openly publishes its results.
Specifically, Tetraphase reports that it is active in a long-term AMR surveillance programme, which focuses on surveillance of eravacycline against Gram-negative and Gram-positive clinical isolates globally.
* Bacteria and fungi that have been identified as priority R&D targets for limiting AMR, by either the WHO and/or the Centers for Disease Control and Prevention (CDC).